Pelthos Therapeutics (PTHS) Income from Continuing Operations (2023 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Income from Continuing Operations of 21664000.0 for Q4 2025, down 1024.82% year-over-year from 2342514.26 in Q4 2024, and down 33.42% quarter-over-quarter from 16238000.0 in Q3 2025.
Pelthos Therapeutics (PTHS) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Pelthos Therapeutics' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 21664000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 1024.82% year-over-year to 21664000.0; the TTM figure through Dec 2025 stood at 36369611.0 (down 357.19% YoY), while the FY2025 annual figure was 43319000.0, down 444.55% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 21664000.0, down from 16238000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3500000.0 in Q2 2025, with the low at 21664000.0 in Q4 2025.
- The 3-year median for Income from Continuing Operations is 1848809.5 (2024), against an average of 4308779.42.
- Peak annual rise in Income from Continuing Operations reached 297.56% in 2025, while the deepest fall reached 1024.82% in 2025.
- Pelthos Therapeutics' Income from Continuing Operations stood at 4039153.0 in 2023, then soared by 52.32% to 1926000.0 in 2024, then tumbled by 1024.82% to 21664000.0 in 2025.
- Business Quant data shows PTHS's Income from Continuing Operations at 21664000.0 in Q4 2025, 16238000.0 in Q3 2025, and 3500000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | -48.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.49 Mn |
| Dec 31, 2025 | -21.66 Mn |
| Sep 30, 2025 | -16.24 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -1.93 Mn |
| Sep 30, 2024 | -1.70 Mn |
| Jun 30, 2024 | -1.77 Mn |
| Mar 31, 2024 | -2.56 Mn |
| Dec 31, 2023 | -4.04 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -953,347.00 |
| Mar 31, 2023 | -966,561.00 |